Key terms
About TRDA
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TRDA news
Mar 18
6:25am ET
Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline
Mar 13
10:25am ET
TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Mar 13
7:08am ET
Entrada Therapeutics expects cash to fund requirements through 2Q26
Mar 13
7:08am ET
Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)
Jan 29
5:14am ET
‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
Jan 05
8:15am ET
Entrada Therapeutics Inc (TRDA) Receives a New Rating from Oppenheimer
Jan 04
4:07pm ET
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Jan 03
7:04am ET
Entrada Therapeutics promotes Dowden to President
No recent news articles are available for TRDA
No recent press releases are available for TRDA
TRDA Financials
Key terms
Ad Feedback
TRDA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TRDA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range